NCT01666613View on ClinicalTrials.gov

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy
Interventions
DRUG

AZD8683

Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683

DRUG

AZD8683

Solution to be administered orally Total dose of 950 µg AZD8683

DRUG

AZD8683

Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683

DRUG

AZD8683

Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY